On June 16, 2021 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that it will host a virtual R&D Day at 10:00 a.m. – 12:00 p.m. ET on Wednesday, June 23, 2021(Press release, Jounce Therapeutics, JUN 16, 2021, View Source [SID1234584042]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature presentations and a Q&A session from Jounce management and scientific team members, in addition to key opinion leader and a Jounce scientific founder, Robert Schreiber, PhD, The Washington University School of Medicine.

A webcast of the R&D Day will be available by visiting "Events and Presentations" in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be available for 30 days following the presentation.

On June 16, 2021 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") reported that Astellas and Cheplapharm Arzneimittel GmbH ("Cheplapharm") have enterd into an Asset Purchase Agreement, under which Astellas will transfer the Products Rights for five legacy products (the "Products") in certain countries of Europe, Russia, Commonwealth of Independent States (CIS)1 and Asia(Press release, Astellas, JUN 16, 2021, View Source [SID1234584040]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Once the transaction closes, Cheplapharm will take over the Products Rights from Astellas and sell them in certain countries of Europe, Russia, CIS and Asia. Astellas will work closely with Cheplapharm to enable a smooth transition.

(1) Purpose of Asset Purchase Agreement
The agreement is a part of Astellas’ ongoing efforts to improve the quality and efficiency of operations so as to accommodate the rapidly changing business environment and achieve sustainable growth. Astellas will continue to strengthen our business presence in Europe, Russia, CIS, and Asia through optimization of resource allocation.

(2) Financial Terms of Asset Purchase Agreement
€95 million

(3) Schedule of Asset Purchase Agreement
June 15, 2021: Signing of the Asset Purchase Agreement
September 2021 or later: Closing of the transaction(tentative)

After closing of the transaction, the Products Rights for the Products will be transferred in each country.

(4) List of the Products

Products Name Indication
FLEMOXIN Acute respiratory infections, Helicobacter pylori associated diseases, such as gastritis and gastric ulcer, urogenital infections and others
DE-NOL Gastro protector with antibacterial effect on H. pylori
SUPRAX Chronic and recurrent respiratory infections with the highest activity towards H. influenzae. Infections caused by susceptible bacteria, such as urinary tract infections and others, e.g. skin, secondary infection in trauma, burn or surgical wound, cholangitis
UNIDOX Infections, such as mild community acquired pneumonia, acute exacerbations of chronic bronchitis, lymphogranuloma venereum, acne vulgaris, chlamydia trachomatis infections, prostatitis, cervicitis and pelvic inflammatory diseases
ORBENINE Infections caused by gram-positive organisms (except MRSA and MRSE), including infections caused by beta-lactamase producing staphylococci

(5) Sales of the Products
€81.5 million(fiscal year ended March 31, 2021)

Astellas has already reflected the impact from this transaction in its financial forecast of the current fiscal year ending March 31, 2022.

On June 15, 2021 Acorda Therapeutics, Inc. (Nasdaq: ACOR) reported that on June 15, 2021, it repaid in full its 1.75% Convertible Senior Notes due 2021(Press release, Acorda Therapeutics, JUN 16, 2021, View Source [SID1234584039]). Prior to their maturity and repayment, there were $69.0 million aggregate principal amount of 2021 notes outstanding. The 2021 notes were repaid using cash on hand.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The repayment of the 2021 notes removes an overhang on the company and is another important milestone in our strategy, following the sale of our manufacturing operations earlier this year. We are focused on accelerating the growth of INBRIJA, continuing to maintain the strength of AMPYRA, and optimizing the company’s financial structure," said Ron Cohen, M.D., Acorda’s President and Chief Executive Officer. "We have maintained cost discipline since our restructuring announcement in February and are continuing to drive toward cash flow breakeven.

On June 16, 2021 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") reported that it will host a virtual investor event on Wednesday, June 23, 2021, at 2 p.m. CEST / 8 a.m. EDT(Press release, Innate Pharma, JUN 16, 2021, View Source [SID1234584032]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature presentations and an interactive Q&A session from the Company’s executive leadership team as well as Martine Bagot, M.D., Ph.D., Professor and Head of the Dermatology Department at the Saint-Louis Hospital, University of Paris, France.

Pr. Bagot will present preliminary mycosis fungoides data from the Company’s Phase 2 TELLOMAK trial evaluating its lead product, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas. This preliminary data will be presented as an oral presentation at the 16th International Conference on Malignant Lymphoma (16-ICML) on June 22.

Additionally, the Company’s Chief Scientific Officer, Pr. Eric Vivier, DVM, Ph.D., will present preclinical data from ANKETTM (Antibody-based NK cell Engager Therapeutics), Innate’s proprietary platform for developing next-generation, multi-functional NK cell engagers. These new data were presented at the Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting on June 10.

On June 15, 2021 Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, reported that Michael K. Schultz PhD, Chief Science Officer of Viewpoint presented at The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, held virtually June 11-15, 2021 (Press release, Viewpoint Molecular Targeting, JUN 15, 2021, https://viewpointmt.com/viewpoint-molecular-targeting-chief-scientific-officer-dr-michael-schultz-discusses-the-promise-of-image-guided-212pb-alpha-particle-radiopharmaceutical-therapies-for-cancer-at-the-snmmi-202/ [SID1234585491]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Schultz presented on Saturday, June 12, 2021, as part of the Continued Education (CE) session titled, "Imaging of Therapeutic Radionuclides for Dosimetry." As part of the session, Dr. Schultz discussed the 203Pb/212Pb image-guided radionuclide therapy paradigm and key innovations that are advancing the approach. Key data presented substantiates the potential of 203Pb imaging as a surrogate for 212Pb therapeutics and the performance of Viewpoint’s chelation technology for delivering radiation specifically to tumors.

Viewpoint is currently advancing its new, proprietary class of personalized 212Pb-based alpha-particle radiopharmaceuticals to transform the treatment landscape of radiotherapies for cancer. Through its unique theranostic approach, the Company’s technology provides the ability to diagnose the tumor and then treat it. This two-step, personalized medicine process helps to identify patients that are more likely to respond to the Company’s therapy and potentially improve efficacy. At the same time, the use of imaging to personalize treatments has the potential to minimize potential toxicities associated with many other types of cancer treatments.

The Company’s image-guided targeted alpha therapies (TAT) leverage specialized targeting peptides to deliver the diagnostic 203Pb and cancer-killing 212Pb directly to the tumor. Targets are carefully selected to ensure they are overexpressed on cancer cells and minimally expressed on normal healthy cells. When the peptide is radiolabled with the Company’s diagnostic 203Pb, the patient can be imaged (i.e., SPECT/CT) to reveal cancer cells in the body. When the peptide is radiolabeled with 212Pb (alpha-particle emitting radiation) the target-peptide binding delivers powerful, yet locally deposited, cancer-killing alpha-particle radiation directly to cancer cells. This targeting mechanism allows for maximized therapeutic effects while minimizing off-target toxicities.

For more information about the Company’s precision oncology therapeutics and complementary diagnostic imaging agents, visit viewpointmt.com.

About The 2021 SNMMI Annual Meeting

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting is recognized as the premier educational, scientific, research, and networking event in nuclear medicine and molecular imaging. The four day event, taking place each June, provides physicians, technologists, pharmacists, laboratory professionals, and scientists with an in-depth view of the latest research and development in the field as well as providing insights into practical applications for the clinic. For more information, visit www.snmmi.org.